APA

Papakostas T. D., Lim L., van Zyl T., Miller J. B., Modjtahedi B. S., Andreoli C. M., Wu D., Young L. H., Kim I. K., Vavvas D. G., Esmaili D. D., Husain D., Eliott D. & Kim L. A. (20160824). Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. : Eye (London, England).

Chicago

Papakostas T D, Lim L, van Zyl T, Miller J B, Modjtahedi B S, Andreoli C M, Wu D, Young L H, Kim I K, Vavvas D G, Esmaili D D, Husain D, Eliott D and Kim L A. 20160824. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. : Eye (London, England).

Harvard

Papakostas T. D., Lim L., van Zyl T., Miller J. B., Modjtahedi B. S., Andreoli C. M., Wu D., Young L. H., Kim I. K., Vavvas D. G., Esmaili D. D., Husain D., Eliott D. and Kim L. A. (20160824). Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. : Eye (London, England).

MLA

Papakostas T D, Lim L, van Zyl T, Miller J B, Modjtahedi B S, Andreoli C M, Wu D, Young L H, Kim I K, Vavvas D G, Esmaili D D, Husain D, Eliott D and Kim L A. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. : Eye (London, England). 20160824.